Gilead gives up on $4.9B antibody as solid tumor plan unravels

A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline.

The program sank deeper into the mire in February, when Gilead ended development in blood cancers and paused enrollment in all solid tumor trials. Gilead pumped the brakes on the solid tumor trials when the FDA asked for a partial clinical hold on the studies. But at that time Gilead was still “reviewing the benefit-risk of magrolimab across all ongoing trials.”

Gilead quietly provided an update on the program after the market closed Thursday, removing all solid tumor trials of the CD47 drug candidate from its pipeline as part of its first quarter results update (PDF). The antibody is now completely absent from Gilead’s pipeline.

Previously, Gilead was…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks